[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353205-105":59,"doc-detail-353205-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","role-of-the-stromal-and-immune-microenvironment-in-intrahepatic-cholangiocarcinoma-summary","Role of the Stromal and Immune Microenvironment in Intrahepatic Cholangiocarcinoma - Summary","","Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal malignancy with an overall ~10% 5-year survival. Surgery and chemotherapy have long been the main approaches, but genomic profiling enabled targeted therapies such as FGFR and IDH inhibitors, which are often limited by rapid resistance. Despite increasing use of immune checkpoint inhibitors in combination with chemotherapy, many patients show intrinsic resistance and only modest survival gains. This review explains how the stromal and immune tumour microenvironment influences progression, stratification, immunophenotypes, and fibroblast heterogeneity, and highlights future research and therapeutic implications.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/role-of-the-stromal-and-immune-microenvironment-in-intrahepatic-cholangiocarcinoma-summary/353205/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/role-of-the-stromal-and-immune-microenvironment-in-intrahepatic-cholangiocarcinoma-summary/353205.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is iCCA so difficult to treat and improve outcomes?","Question",{"text":113,"@type":114},"iCCA has an aggressive course and often develops resistance to both targeted therapies and immunotherapies, leading to progression despite treatment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What role does the tumour microenvironment play in iCCA?",{"text":118,"@type":114},"The review attributes therapeutic resistance and the refractory nature of iCCA to the intricate tumour microenvironment, including interactions between tumour cells and immune cells, cancer-associated fibroblasts, and endothelial cells.",{"name":120,"@type":111,"acceptedAnswer":121},"How do genomic and immune features influence patient stratification in iCCA?",{"text":122,"@type":114},"Characterisation of the genomic landscape supports molecular classification and suggests distinct genotype–immunophenotype relationships that can inform patient stratification.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},353205,1790393516,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nRole of the stromal and immune microenvironment in  \nintrahepatic cholangiocarcinoma q  \nSilvia Affo1 , ∗ , Daniela Sia2 , ∗  \nSummary  \nIntrahepatic cholangiocarcinoma (iCCA) is one of the deadliest malignancies, with an overall 5-year survival rate of approximately 10% . For decades, surgery and chemotherapy have represented the only treatment options for early-and late-stage disease, respectively. More recently, characterisation of the genomic landscape of iCCA has identified several “druggable” oncogenicdrivers and led to the FDA approval of the first targeted therapies, including FGFR and IDH inhibitors, for second-line treatment in genetically defined patient subsets. Nonetheless, most patients treated with these therapies rapidly develop resistance and eventually experience disease progression. At a time when immune checkpoint inhibitors (ICIs) are profoundly reshaping cancer treatment, their use in combination with chemotherapy has yielded only modest survival benefits in iCCA, with more than twothirds of patients exhibiting intrinsic resistance. The aggressive and refractory nature of this cancer is often attributed to its intricate tumour microenvironment (TME); however, the complex interplay between tumour cells and other TME components (i.e. immune cells, cancer-associated fibroblasts, and endothelial cells), as well as the molecular and cellular mechanisms driving tumour progression and therapeutic resistance, remain poorly understood. In this review, we discuss the critical role of the stromal and immune TME in iCCA and how its characterisation has informed patient stratification and molecular classification. We also describe recent findings supporting distinct genotype–immunophenotype relationships in iCCA, as well as the existence of functionally heterogeneous subsets of cancer-associated fibroblasts. Ultimately, this review aims to provide a comprehensive overview of current knowledge while stimulating discussion on therapeutic implications and future research directions.  \n© 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL) . This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \nIntroduction  \nPrimary liver cancer represents the third leading cause of cancer-related death globally.1 ,2 The second most common primary liver cancer (􀀙 15%-20%) after hepatocellular carcinoma is intrahepatic cholangiocarcinoma (iCCA), an aggressive malignancy of the small bile ducts within the liver.3 ,4 Based on the anatomical location, iCCA is often grouped together with other biliary tract cancers (BTC) including extrahepatic forms of cholangiocarcinoma (CCA) – perihilarand distal – and gallbladder cancer. However, it is well accepted that crucial differences exist among the distinct BTCs and between the CCA subtypes both in terms of genetic landscape,5 potential cell-of-origin,6 and management,3 ,4 ,7 suggesting that they represent distinct molecular and clinical entities. Here, we will focus on understanding the tumour microenvironment (TME) of iCCA.  \nWith an incidence of 1–2 new cases per 100,000 persons per year in the US, iCCA is a relatively rare but highly fatal malignancy, accounting for less than 3% of all gastrointestinal cancers yet nearly 20% of related deaths.3 Despite its low prevalence, a steady increase in its incidence8 and mortality9  \nrates has been recorded over recent decades. In the US alone, the incidence of iCCA increased by 128% between 1973 and 201210 and continues to rise.11 This steady increase, combined with high mortality rates,9 underscores the fact that optimal management of iCCA remains a challenge. Importantly, while epidemiological studies have reported increasing incidence and mortality rates for iCCA, rates for extrahepatic CCA have been steady or decreasing.6 Although rare in the Western world, iCCA is the most common liver","cbCaifKCCZPMGNPD","https://ap.wps.com/l/cbCaifKCCZPMGNPD","pdf",6597595,14,"English","# Summary\n# Introduction\n# Keypoints","[{\"question\":\"Why is iCCA so difficult to treat and improve outcomes?\",\"answer\":\"iCCA has an aggressive course and often develops resistance to both targeted therapies and immunotherapies, leading to progression despite treatment.\"},{\"question\":\"What role does the tumour microenvironment play in iCCA?\",\"answer\":\"The review attributes therapeutic resistance and the refractory nature of iCCA to the intricate tumour microenvironment, including interactions between tumour cells and immune cells, cancer-associated fibroblasts, and endothelial cells.\"},{\"question\":\"How do genomic and immune features influence patient stratification in iCCA?\",\"answer\":\"Characterisation of the genomic landscape supports molecular classification and suggests distinct genotype–immunophenotype relationships that can inform patient stratification.\"}]","Role of the Stromal and Immune Microenvironment in Intrahepatic Cholangiocarcinoma - Summary | PDF",1790103569,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b91e44711201015be18513fe0f9d5f4.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb747b339c91cf37e4fb5cf2c2c08589.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e16f9c1a098da699e2130a4cdde1dd4.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f619d7104198819edcd7297ba75f68a5.webp",980,1306]